PARIS, March 09, 2026 (GLOBE NEWSWIRE) -- kyron.bio, a biotechnology company pioneering precision glycoengineering for antibody therapeutic ...

Non-CHO cell expression systems gain traction as faster, more flexible alternatives for biologics manufacturing.

Aberrant Glycosylation Drives Kidney Disease Pathogenesis. This schematic illustrates how abnormal glycosylation contributes to diverse kidney diseases: (A) galactose-deficient IgA1 in ...

Therapeutic antibodies are among the most widely used biologic medicines, yet detecting subtle structural differences in these complex proteins remains challenging. Researchers in Japan have ...

Kidney diseases affect nearly 700 million people worldwide and are a growing cause of mortality and health care costs. Chronic kidney disease (CKD) alone contributes to over 1.2 million deaths ...

Research captures how the GRP94 protein shields itself to make sure it forms properly and suggests a way to target it for future disease treatments. Proteins are often called the building blocks of ...

Making proteins for research or therapies often starts with cell-line development. In many applications, genetic engineering is used to optimize a cell line for producing high levels of the intended ...

Explore how proteomics enables personalized medicine by improving patient stratification, treatment response, and diagnostics ...

The blood–brain barrier, a selective, semipermeable border around the central nervous system, is the body’s built-in mechanism to protect these critical areas from unwanted intruders like toxins and ...